Big Pharma says AI is cutting early drug discovery timelines by as much as half
GSK, Bristol Myers Squibb, Novartis, Eli Lilly, Novo Nordisk, AstraZeneca and Sanofi told Reuters they now use AI to design molecules, rank candidates and flag safety risks, as Anthropic pushes into drug discovery.
Why it matters
The drugmakers say AI has moved past paperwork such as regulatory filings into the core of discovery, and some argue decades of their own data give them an edge over AI labs. Anthropic, which listed this week, has opened its own laboratory and announced investments to speed drug discovery. Industry group PhRMA says nearly nine in ten conventionally developed drugs fail in trials and a new medicine can take 10 to 15 years. Lilly's Aliza Apple said claims that AI can cure all disease overstate current capabilities. Watch whether faster discovery shows up in clinical success rates.
Key facts
- AI has cut the time to produce new molecules and move them into the clinic by as much as half at some companies
- Sanofi says it saved at least a year developing asthma drug lunsekimig
- Novartis says AI helped it find five kidney-disease targets
- AstraZeneca's Sharon Barr: 'There is no part of the discovery through development pipeline where we are not using AI'
- PhRMA: nearly 9 in 10 conventionally developed drugs fail in clinical trials